tusamitamab ravtansine + ramucirumab + pembrolizumab

Tusamitamab ravtansine + ramucirumab + pembrolizumab is a combination regimen in clinical development for advanced solid tumors. - **Tusamitamab ravtansine** is an antibody-drug conjugate that targets the carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) on tumor cells. It consists of a humanized IgG1 monoclonal antibody conjugated with a cytotoxic maytansinoid derivative (DM4) via a covalent linker. After binding to CEACAM5 on tumor cells, the conjugate is internalized and releases DM4, which inhibits microtubule assembly, leading to cell death[2][4][7]. - **Ramucirumab** is a fully human monoclonal antibody that targets vascular endothelial growth factor receptor 2 (VEGFR2), thereby inhibiting receptor activation and angiogenesis, which is essential for tumor growth and metastasis. - **Pembrolizumab (Keytruda)** is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1), resulting in immune checkpoint inhibition and activation of T-cell mediated antitumor immunity[6]. This regimen is being explored for the treatment of various advanced cancers, including gastric cancer and possibly other solid tumor types, predominantly via intravenous administration[8].